Tag: Aquestive Therapeutics

Aquestive AQST-109 Epinephrine Film

Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial

Phase 2 study continues to show AQST-109 is safe and well tolerated.
Needless Epinephrine Alternatives

They’re Coming: Needle-Free Emergency Epinephrine Options Currently in Trials

For some, the needle is a barrier to administration but alternatives are on the horizon.
Epinephrine Development in Stealth Mode

Stealth Mode Company Granted Patent for Sublingual Epinephrine Tablet

We've been reporting on the progress of AQST-109 by Aquestive Therapeutics, a postage-stamp-sized film placed under the tongue that provides epinephrine in an anaphylactic...
Aquestive AQST-109 Epinephrine Film

Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA

AQST-109 is the first orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions including anaphylaxis.
Neffy Intranasal Epinephrine Device

CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...

The market for epinephrine delivery may expand to include non-needle alternatives next year.
Aquestive's Subingual Epinephrine

Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration

Company presented top level Phase 1 results at #AAAAI2022 meeting.
Aquestive AQST-109 Epinephrine Film

Sublingual Emergency Epinephrine Takes Another Step Forward in Phase 1 Study

Aquestive's postage-stamp-sized film is designed to dissolve under the tongue to provide epinephrine.
Aquestive's Subingual Epinephrine

Aquestive Charts Ambitious Path Forward for Sublingual Emergency Epinephrine

Company updates the public on status of their candidate drug administered under the tongue.
AQST-108 Phase 1

Emergency Epinephrine Film Begins Phase 1 Clinical Trials

First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis.
Aquestive AQST-109 Epinephrine Film

Aquestive’s Sublingual Epinephrine Film Receives FDA Fast Track Designation for Treatment...

First planned PK clinical trial expected to begin during the third quarter of 2020.